What is Medlab?
Medlab, Inc. operates as a sophisticated clinical laboratory enterprise, delivering high-precision testing services across toxicology, molecular diagnostics, and pain management. The firm distinguishes itself through a robust service portfolio that includes rapid PCR testing for respiratory pathogens such as COVID-19, Influenza, and RSV. By providing same or next-day results, Medlab serves as a vital partner for healthcare providers, judicial systems, and community health entities. Their operational model is built upon advanced testing technologies that prioritize accuracy and turnaround speed, effectively addressing the diagnostic needs of patients and providers in both clinical and forensic settings.
How much funding has Medlab raised?
Medlab has raised a total of $16.3M across 2 funding rounds:
Series D
$16M
Debt
$250K
Series D (2008): $16M with participation from Primus Capital, Oxford Bioscience Partners, and Chrysalis Ventures
Debt (2025): $250K led by M&T Bank
Key Investors in Medlab
Primus Capital
Primus Capital is a U.S.-based growth-oriented private equity firm that invests in healthcare, software, and technology-enabled services companies, providing equity capital for buyouts and expansion.
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology-based investments, with offices in Boston, Massachusetts and Seoul, Korea.
Chrysalis Ventures
Chrysalis Ventures is an investment firm based in Louisville, KY, that focuses on partnering with proven operators in markets underserved by technology, including healthcare and logistics.
What's next for Medlab?
With the successful procurement of this latest capital, Medlab is well-positioned to enhance its diagnostic throughput and expand its technological footprint. The strategic focus will likely shift toward optimizing laboratory automation and scaling its molecular diagnostic platforms to meet the rising demand for rapid, insurance-reimbursable testing. As the company navigates the current healthcare landscape, this infusion of liquidity provides the necessary runway to pursue operational efficiencies and potentially broaden its service offerings in chronic pain management and substance abuse diagnostics. Investors will be monitoring how Medlab utilizes this debt financing to maintain its competitive edge against emerging diagnostic startups and established laboratory networks.
See full Medlab company page
